1. Scrip
  2. >>Drug Pricing

Humira's Inevitable Decline: What's Waiting In The Wings?

 
• By Lucie Ellis-Taitt

There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.

Business decline
World's best-selling drug Humira faces big losses as biosimilar versions wait in line • Source: Shutterstock

Biosimilar versions of the world's bestselling drug, AbbVie Inc.'s Humira (adalimumab), are lurking all over the globe in shadows cast by the originator product, ready to hit the market as soon as patent protection is lost for the drug, which is the major engine driving AbbVie's revenues and profits.

Humira, a tumor necrosis factor (TNF) inhibitor approved for several inflammatory indications, is still the main source of growth for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

More from Scrip

Vertex Heralds ‘Unprecedented’ Zimislecel Type 1 Diabetes Data

 
• By Kevin Grogan

The off-the-shelf stem cell therapy shows sustained glycemic control and a high rate of insulin independence.

Pipeline Watch: Ten Approvals And Seventeen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Obesity Treatment Could Go Global With Lilly’s Orforglipron

 
• By Andrew McConaghie

The company’s oral GLP-1 candidate has reassured on its safety at the American Diabetes Association meeting, convincing analysts it will open up new global markets.